What is EVOluTION?

EVOluTION is a Marie Sklodowska-Curie Actions Innovative Training Network (ITN) doctoral programme. It has been designed to provide multidisciplinary training for 11 PhD students on various aspects of drug discovery and development including: preclinical and clinical research, commercial and business opportunities and intellectual property.

The science of EVOluTION is based on boosting the natural protective mechanisms operating in our body, to generate innovative therapeutic strategies in the management of chronic vascular and metabolic diseases.

Objectives

The 4 main research objectives are to investigate:

- Mechanisms by which dietary approaches boost tissue protection
- Endogenous tissue protective mediators
- Pro-Resolving Receptors
- Proof-of-concept approaches for innovative therapeutics

The interdisciplinary and cross-cutting research performed by the Early Stage Researchers in this programme will lead to novel therapeutic tools and a scientific perspective to address challenging medical, societal and industrial issues. Moreover, this ITN will deliver high level scientific and complementary training to create a new generation of scientists that are entrepreneurially minded and skilled in research and business.

For further information
Contact: Annabelle Scott
a.n.scott@qmul.ac.uk
Website:
http://www.qmul.ac.uk/evolution

The interdisciplinary and cross-cutting research performed by the Early Stage Researchers in this programme will lead to novel therapeutic tools and a scientific perspective to address challenging medical, societal and industrial issues. Moreover, this ITN will deliver high level scientific and complementary training to create a new generation of scientists that are entrepreneurially minded and skilled in research and business.

Partners

Associated Partners

Genomics England, U.K.
Kilburn and Strode, U.K.
NattoPharma, Norway
MosaMedix B. V., Netherlands
Quintiles LTD, U.K.
Royal Society of Chemistry, U.K.
UCB Pharma S.A., U.K.
William Harvey Research Ltd, U.K.